Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Comprehensive Approach to Improve Medication Adherence in Pediatric ALL. For a description of this project, see the consortium grant made to the lead institution: the University of Alabama at Birmingham, Birmingham, AL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Comprehensive Approach to Improve Medication Adherence in Pediatric ALL. For a description of this project, see the consortium grant made to the lead institution: the University of Alabama at Birmingham, Birmingham, AL.

Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma. The two main subtypes, embryonal and alveolar, are defined by their appearance under the microscope. However, identification of a unique gene mutation in alveolar rhabdomyosarcoma identifies a subgroup with worse prognosis. Future studies may use this gene mutation rather than microscopic appearance to determine risk stratification and treatment, but before instituting this strategy researchers must confirm the role of fusion status in low-risk and metastatic rhabdomyosarcoma. This consortium is examining low-risk and high-risk clinical trials of the COG (Children's Oncology Group) to confirm the importance of fusion status in determining treatment for patients with rhabdomyosarcoma. Awarded at Oregon Health & Science University and transferred to Seattle Children's Hospital.

One of 5 children with acute lymphoblastic leukemia suffers a relapse within 5 years of diagnosis. Also, Hispanic and African American children are more likely to relapse. Research has shown that 44% of the children are non-adherent to oral chemotherapy and that non-adherence is associated with an increased risk of relapse. This consortium has created a comprehensive package of interventions to improve adherence to oral chemotherapy. It is believed that this improvement in adherence will directly translate into an improvement in survival and a higher number of children cured of their cancer. Awarded at the Beckman Research Institute of the City of Hope and transferred to the University of Alabama at Birmingham. Funds administered by the University of Alabama at Birmingham.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Prognostic significance of gene fusion in low or high risk rhabdomyosarcoma. For a description of this project, see the consortium grant made to the lead institution: Seattle Children's Hospital, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Comprehensive Approach to Improve Medication Adherence in Pediatric ALL. For a description of this project, see the consortium grant made to the lead institution: the University of Alabama at Birmingham, Birmingham, AL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Prognostic significance of gene fusion in low or high risk rhabdomyosarcoma. For a description of this project, see the consortium grant made to the lead institution: Seattle Children's Hospital, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Prognostic significance of gene fusion in low or high risk rhabdomyosarcoma. For a description of this project, see the consortium grant made to the lead institution: Seattle Children's Hospital, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Prognostic significance of gene fusion in low or high risk rhabdomyosarcoma. For a description of this project, see the consortium grant made to the lead institution: Seattle Children's Hospital, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Prognostic significance of gene fusion in low or high risk rhabdomyosarcoma. For a description of this project, see the consortium grant made to the lead institution: Seattle Children's Hospital, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Comprehensive Approach to Improve Medication Adherence in Pediatric ALL. For a description of this project, see the consortium grant made to the lead institution: the University of Alabama at Birmingham, Birmingham, AL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Comprehensive Approach to Improve Medication Adherence in Pediatric ALL. For a description of this project, see the consortium grant made to the lead institution: the University of Alabama at Birmingham, Birmingham, AL.

Based on progress to date, Dr. Davis was awarded a new grant in 2014 to fund an optional third year of this fellowship. Cancer affects teenagers and young adults more often than young children, but these in-between aged people have lower survival rates than yonger children. There aren't many doctors that specialize in treating these patients, but that is exactly what Dr. Davis is training to do. As part of this training, she is studying a bone cancer that occurs in teens. This same cancer affects pet dogs, too. She is testing drugs in a lab to see which ones kill the most tumor cells and then investigatimg why they work, in hopes that it will help both kids and dogs with this tumor live longer.

Adaptive cell therapy involves engineering the body's own immune cells, called T-cells, to fight cancer. The T-cells are engineered to target a protein which is present only in the cancer cells, but not in normal cells. One such protein, WT-1 is expressed only in leukemia cells and has proven to be an effective target, for a specific type of T cells called CD8 T-cells. However, these CD8 T-cells do not persist and leukemias recur. Dr. Anur Praveen, PartnerRe St. Baldrick's Fellow, is studying whether another type of T-cells called CD4 T-cells alone can eradicate leukemia or these CD4 T cells can help the CD8 T-cells to last longer and fight leukemia without recurrence. This grant is named for PartnerRe, a global reinsurance company who has raised over $1 million to fund childhood cancer research through the St. Baldrick’s Foundation.

This grant funded a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funded a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funds a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funded a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funded a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funded a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.